Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Tetsu, Kamitani"'
Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
Autor:
Yasushi Goto, MD, PhD, Kodai Kawamura, MD, PhD, Tatsuro Fukuhara, MD, PhD, Yukiko Namba, MD, PhD, Keisuke Aoe, MD, PhD, Takehito Shukuya, MD, PhD, Takeshi Tsuda, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD
Publikováno v:
Current Therapeutic Research, Vol 99, Iss , Pp 100712- (2023)
ABSTRACT: Background: First-line immune checkpoint inhibitor (ICI) monotherapy for advanced non–small cell lung cancer (NSCLC) was introduced in Japan in February 2017. Limited information is available since that time regarding health care resource
Externí odkaz:
https://doaj.org/article/56826401c91e4ca1b5e8511e8fa71b5f
Autor:
Yasushi Goto, MD, PhD, Atsuhisa Tamura, MD, PhD, Hirotaka Matsumoto, MD, Kazutoshi Isobe, MD, PhD, Tomohiro Ozaki, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100397- (2022)
Introduction: Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. This ret
Externí odkaz:
https://doaj.org/article/6c1d51a111954179b8993ec6b3e61d62
Autor:
Nobuyuki Yamamoto, Tetsu Kamitani, Kingo Kanda, Yuichiro Ito, Masahiro Hamada, Masahiko Ozaki, Noriko Takeuchi, Tomoko Yamada, Masaki Kawano, Shinichiroh Maekawa, Terufumi Kato
Publikováno v:
Cancer Science. 113:3110-3119
This post-marketing surveillance (PMS) was initiated in Japan to identify factors affecting the safety and effectiveness of pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with programmed cell death ligand-1 (PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e83d0424a67487ea5f533a0e2148c91
https://doi.org/10.1111/cas.15439
https://doi.org/10.1111/cas.15439
Autor:
Kunikazu Tanji, Tetsu Kamitani, Fumiaki Mori, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi
Publikováno v:
Neurobiology of Disease, Vol 38, Iss 2, Pp 210-218 (2010)
TRIM family proteins are involved in a broad range of biological processes, and their alteration results in many diverse pathological conditions found in genetic diseases, viral infections, and cancers. However, the spatial and temporal expression an
Externí odkaz:
https://doaj.org/article/09caf332457c430b832454997b3969d9
Autor:
Hiroshi Nokihara, Takashi Kijima, Toshihide Yokoyama, Hiroshi Kagamu, Takuji Suzuki, Masahide Mori, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, Yasushi Goto
Publikováno v:
Cancers; Volume 14; Issue 12; Pages: 2846
The aims of this study were to describe systemic treatment patterns and clinical outcomes for unresectable advanced/metastatic non-small-cell lung cancer (NSCLC) by first-line regimen type in real-world clinical settings in Japan after the introducti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ca921e0468e08a9d23e24d718e8293
https://doi.org/10.3390/cancers14122846
https://doi.org/10.3390/cancers14122846
Autor:
Byung Rho Lee, Tetsu Kamitani
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23939 (2011)
α-Synuclein is a key molecule in understanding the pathogenesis of neurodegenerative α-synucleinopathies such as Parkinson's disease. Despite extensive research, however, its precise function remains unclear partly because of a difficulty in immuno
Externí odkaz:
https://doaj.org/article/35a8da23e3b84dc4ba054a01291198cb
Autor:
Yasuhiro Matsuo, Tetsu Kamitani
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10481 (2010)
Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma
Externí odkaz:
https://doaj.org/article/69ae7b80826d44eca9ab9d062b7fc77d
Autor:
Koichi Wakabayashi, Kunikazu Tanji, Atsushi Maruyama, Junsei Mimura, Ken Itoh, Yasuo Miki, Fumiaki Mori, Tetsu Kamitani
Publikováno v:
Biochemical and Biophysical Research Communications. 470:635-642
Abnormal α-synuclein is deposited in neuronal cytoplasmic inclusions and presynapses in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Previously we have shown that NUB1 is accumulated in these specific regions together with abnormal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517af9d696b5b60f1e9ad5cd821474ee
https://doi.org/10.1016/j.bbrc.2016.01.093
https://doi.org/10.1016/j.bbrc.2016.01.093
Publikováno v:
Current Pharmaceutical Design. 19:4131-4139
Tumor cells frequently promote the dysregulation of the cell cycle and escape from apoptotic cell death triggered by a number of cellular stresses. Programmed proteolytic degradation of regulatory proteins via the ubiquitin-proteasome pathway is cruc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd7cc2b01a6cf5f60d0974f791a00d8
https://doi.org/10.2174/1381612811319220017
https://doi.org/10.2174/1381612811319220017
Publikováno v:
Journal of Cell Science. 126:696-704
Summary α-Synuclein, a protein central to Parkinson's disease, is frequently expressed in melanoma tissues, but not in non-melanocytic cutaneous carcinoma and normal skin. Thus, α-synuclein is not only related to Parkinson's disease, but also to me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d300324197209f55f08311f736ce8d2
https://doi.org/10.1242/jcs.122093
https://doi.org/10.1242/jcs.122093